Abstract 1782P
Background
Men with advanced prostate cancer are at risk of upper urinary tract obstruction (UUTO) due to local progression leading to increased morbidity. Primary site radiotherapy (RT) improves overall survival in patients with low volume metastatic hormone sensitive prostate cancer (mHSPC), with limited data available to demonstrate its impact on local progression. Accessible, high quality healthcare systems data (HSD) provides accurate event data beyond standard trial follow up, permitting evaluation of the impact of primary RT on need for UUTO interventions.
Methods
Linked HSD from Hospital Episode Statistics (HES) with follow-up to March 2021 were available for patients randomised 1:1 in England between arms A (standard of care [SOC]) and H (SOC+RT). Radiotherapy was delivered either daily: 55 Gy in 20 fractions over 4 weeks or weekly: 36 Gy in six fractions over 6 weeks. Interventions for UUTO (including percutaneous nephrostomy and or ureteric stent insertion) were identified using a comprehensive coding framework using International Classification of Diseases (ICD 10) diagnosis and Classification of Interventions and Procedures (OPCS 4) codes Multivariate flexible parametric survival models adjusted for randomisation stratification factors were used to estimate the treatment effect of primary RT on the cumulative incidence of UUTO and sub distribution hazard ratios (SDHR).
Results
1791/2061 (88%) were followed up by English hospitals; connected HSD were available for 1724/1791 (96%). After excluding 19 patients who had a UUTO intervention in the 90 days leading to randomisation, model-based 5-year incidence of UUTO requiring intervention was 5% [4; 7%] in patients randomised to SOC, and 3% [2; 4%] in patients randomised to SOC + RT (SDHR 0.568, 95% CI 0.353-0.912; p=0.017). Treatment effects were comparable in high- and low-volume metastasis subgroups.
Conclusions
UUTO interventions are performed in a modest proportion of mHSPC patients. Prostate radiotherapy significantly reduced the use of UUTO interventions. These data support the use of prostate radiotherapy in men with mHSPC at risk of UUTO.
Clinical trial identification
NCT00268476.
Editorial acknowledgement
Legal entity responsible for the study
MRC Clinical Trials Unit and UCL.
Funding
Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis.
Disclosure
C. Jones: Financial Interests, Personal, Invited Speaker: Janssen. P. Dutey-Magni, M.R. Sydes: Financial Interests, Institutional, Research Funding: Janssen, Astellas, Novartis, Sanofi, and Clovis. L.R. Murphy, M. Murray, L.C. Brown: Non-Financial Interests, Institutional, Research Funding: Janssen, Astellas, Novartis, Sanofi, and Clovis. N.D. James: Financial Interests, Personal, Advisory Board, Advice around PARP inhibitors: AstraZeneca; Financial Interests, Personal, Advisory Board, Prostate cancer therapies: Janssen, Clovis, Novartis; Financial Interests, Institutional, Advisory Board, Assisted with submissions regarding licensing for abiraterone: Janssen; Financial Interests, Personal, Advisory Board, Docetaxel: Sanofi; Financial Interests, Institutional, Advisory Board, Providing STAMPEDE trial data to facilitate license extensions internationally for docetaxel: Sanofi; Financial Interests, Personal, Advisory Board, Bladder cancer therapy: Merck; Financial Interests, Personal, Advisory Board, Advice around novel hormone therapies for prostate cancer: Bayer; Financial Interests, Personal, Invited Speaker, Lecture tour in Brazil August 2022 - speaking on therapy for advanced prostate cancer: Merck Sharp & Dohme (UK) Limited; Financial Interests, Institutional, Coordinating PI, Funding for STAMPEDE trial: Janssen, Astellas; Financial Interests, Institutional, Coordinating PI, Funding for RADIO trial bladder cancer: AstraZeneca. C. Parker: Other, Personal, Advisory Board: ITM Radiopharma; Financial Interests, Institutional, Advisory Board: AAA. N.W. Clarke: Financial Interests, Personal, Invited Speaker: Janssen, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14